Fundraising Fox
Dan Lynch
InvestorExecutive Venture Partner at GV (Google Ventures) · Executive at SpringWorks Therapeutics
Boston, Massachusetts
Writes $250K – $50M checks · typically $25M
Find your path to Dan
406 people in our graph can introduce you to Dan.
Each arrow is one introduction. Sign up to fill in the first one.
Ask Nessan Bermingham to introduce you to Dan
You →Nessan · together at Xilio Therapeutics (2020) →Dan
Ask Jamie Chen to introduce you to Dan
You →Jamie · 2 people · together at Xilio Therapeutics →Dan
Ask Sam Okafor to introduce you to Dan
You →Sam · 5 people · together at Blueprint Medicines →Dan
Sign up to find every way you can get introduced to Dan
- Your email: the people you already email who know Dan
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Dan
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
About
Dan Lynch joined GV in 2021 as an Executive Venture Partner, advising life sciences CEOs and executives while investing in biopharmaceutical companies. Since 2007 he has served as executive chair or board member for numerous biotech firms, and he previously was CEO and CFO of ImClone Systems, where he helped secure FDA approval of the cancer treatment ERBITUX. He also worked at Third Rock Ventures and held financial roles at Bristol-Myers Squibb, and holds a B.A. in mathematics from Wesleyan University and an M.B.A. from the University of Virginia's Darden School.
Likely email· guessed from name + firm domain, not firm-published
- d•••@gv.comreveal100% confident
Invests in
BiotechDigital HealthMedical Devices
Executive at SpringWorks Therapeutics
Intro paths
In turn, Dan can intro founders to SpringWorks Therapeutics's investors below.
SpringWorks Therapeutics's investors · 8
Experience
- Xilio, SpringWorks, bluebird, Blueprint, TranslateChairman of the Boardcurrent2008 — present
- Xilio Therapeutics, Inc.Chairman Of The Boardcurrent2020 — present
- SpringWorks TherapeuticsChairman of the Boardcurrent2017 — presentstamford, ct
- Blueprint MedicinesChairman Of The Boardcurrent2012 — presentCambridge, MA
- Translate BioChairman Of The Boardcurrent2012 — presentCambridge, MA
Investments
Board seats
2Seventy BioAlpha Omega SPACAvila TherapeuticsBIND BiosciencesBlueprint MedicinesEdimer PharmaceuticalseGenesis BioEmber TherapeuticsNimbus DiscoveryProclara BiosciencesSesen BioSpringWorks TherapeuticsStromedixSurface OncologyXilio Therapeutics
Investor
Blueprint MedicinesSesen BioTome Biosciences
Sources: the firm's website · curated public sources.
Colleagues at GV (Google Ventures)
Network9
Investors connected to Dan in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Dan Lynch?
- Dan Lynch joined GV in 2021 as an Executive Venture Partner, advising life sciences CEOs and executives while investing in biopharmaceutical companies. Since 2007 he has served as executive chair or board member for numerous biotech firms, and he previously was CEO and CFO of ImClone Systems, where he helped secure FDA approval of the cancer treatment ERBITUX. He also worked at Third Rock Ventures and held financial roles at Bristol-Myers Squibb, and holds a B.A. in mathematics from Wesleyan University and an M.B.A. from the University of Virginia's Darden School.
- Where does Dan Lynch work?
- Dan Lynch is Executive Venture Partner at GV (Google Ventures) and Executive at SpringWorks Therapeutics.
- What does Dan Lynch invest in?
- Dan Lynch invests in Biotech, Digital Health, Medical Devices.
- What check size does Dan Lynch write?
- Dan Lynch typically writes checks of $250K – $50M.
- What boards does Dan Lynch sit on?
- Dan Lynch holds tracked board seats at 2Seventy Bio, Alpha Omega SPAC, Avila Therapeutics, BIND Biosciences, Blueprint Medicines, Edimer Pharmaceuticals, eGenesis Bio, Ember Therapeutics, Nimbus Discovery, Proclara Biosciences.
- What companies has Dan Lynch invested in?
- Investments tracked here include Blueprint Medicines, Sesen Bio, Tome Biosciences.
- Where did Dan Lynch go to school?
- Dan Lynch studied at University of Virginia Darden School of Business (MBA); Wesleyan University (Bachelor of Arts (B.A.), Mathematics).
Same school
Also attended University of Virginia Darden School of Business238
+ 232 more
Also attended Wesleyan University139
+ 133 more
Shared employers
Also worked at Xilio Therapeutics, Inc.8
+ 2 more
Also worked at SpringWorks Therapeutics4
Also worked at Blueprint Medicines11
+ 5 more
